Selecta’s Data in Q3: De-Risking Event, Not a Delay
Insights - Selecta held a conference call to discuss their Q4 2017 results and provided a corporate update. Overall, we believe the call was positive and shed light … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
A Second KOL’s Thoughts on Selecta
Insights - On March 20th, 2018 SlingShot Insights hosted a KOL call with Dr. Dr Gail Kerr – MD, discussing Selecta (SELB) candidate SEL-212 and Krystexxa, the … Continue Reading
Premium
Fennec’s Fast Track & Breakthrough Designations Pointing to Smooth FDA Review
Insights - This morning, Fennec (FENC) announced that the FDA had granted the company’s candidate, Pedmark, Breakthrough Therapy Designation for the prevention of cisplatin-related ototoxicity in pediatric patients with … Continue Reading
Read nowTranscript of Selecta (SELB) Q4 2017 Conference Call and Corporate Update
Interviews - Operator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Thank you for holding. Welcome to the Selecta Biosciences fourth quarter and year end 2017 conference call. Currently all participants are in a listen … Continue Reading
Read nowHere is What a KOL Had to Say About Selecta
Insights - On Thursday, March 8th, 2018 SlingShot Insights hosted a KOL call with Dr.Vibeke Strand, discussing Selecta (SELB) and the current treatments for gout. Below are … Continue Reading
Premium
GBT’s Latest Financing Could Mean Pipeline Expansion is in the Works
Insights - After market close on Thursday, Global Blood Therapeutics (GBT) announced an offering of 4M shares with a 30-day option to purchase additional 600,000 shares at $54/share. This … Continue Reading
Premium